PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the ...

PTC Inc. is warning of a critical vulnerability in Windchill and FlexPLM, widely used product lifecycle management (PLM) solutions, that could allow remote code execution. The security issue, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for ...

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it ...

PTC Inc. (NASDAQ:PTC) Q1 2026 Earnings Call Transcript February 4, 2026 PTC Inc. beats earnings expectations. Reported EPS is $119797.12, expectations were $1.59. Operator: Good evening, ladies and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

PTC Inc. (PTC) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.98 per share a year ago. These figures are ...

PTC Therapeutics reported a phase 2 win for its Novartis-partnered Huntington's disease candidate. But the readout failed to convince investors, who wiped almost 20% off PTC’s share price amid doubts ...

The biotech’s Huntingtin-targeting molecule lowered blood levels of the protein and elicited functional improvements in earlier-stage patients, but results were not as robust in other biomarkers or ...